CNBC September 14, 2024
Key Points
– Pfizer said its experimental drug for a common, life-threatening condition that causes cancer patients to lose their appetite and weight showed positive results in a midstage trial.
– Patients with the condition, called cancer cachexia, who took Pfizer’s treatment saw improvements in body weight, muscle mass, quality of life and physical function.
– The results could pave the way for the drug, a monoclonal antibody called ponsegromab, to become the first treatment approved specifically for cancer cachexia.
Pfizer‘s experimental drug for a common, life-threatening condition that causes cancer patients to lose their appetite and weight showed positive results in a midstage trial, the drugmaker said Saturday.
Patients with the condition, called cancer cachexia, who took...
Today's Sponsors
Today's Sponsor